At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 171 enrolled
Drug / intervention
Rayaldee +1 moredrug
Likely dose
Rayaldee 30 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of Rayaldee (Calcifediol) Extended-release Capsules to Treat Symptomatic Patients Infected With SARS-CoV-2 (REsCue)
In Brief
A Phase 2 clinical trial evaluating Rayaldee and Placebo for COVID-19 and 2 related conditions. Completed, enrolled 171 participants across 10 sites.
Detailed Summary
This is a phase 2, single or multi-center, randomized, double-blind placebo-controlled study to evaluate the safety and efficacy of Rayaldee (CTAP101 Capsules) to treat adult subjects with mild to moderate COVID-19 who test positive for SARS-CoV-2.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19, Coronavirus, SARS-CoV2 Infection
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedSep 2020
Enrollment StartNov 2020
Primary CompletionOct 2021
TodayJul 2026
First PostedSep 16, 2020
Enrollment StartNov 2, 2020
Primary CompletionOct 8, 2021
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 5.8 years ago
Interventions
Rayaldeedrug
30 mcg calcifediol Extended-Release (ER) Capsule
Placebodrug
0 mcg calcifediol Extended-Release (ER) Capsule